Variant Spectrum of Formin Homology 2 Domain-Containing 3 Gene in Chinese Patients With Hypertrophic Cardiomyopathy
- PMID: 33586461
- PMCID: PMC8174292
- DOI: 10.1161/JAHA.120.018236
Variant Spectrum of Formin Homology 2 Domain-Containing 3 Gene in Chinese Patients With Hypertrophic Cardiomyopathy
Abstract
Background The FHOD3 (formin homology 2 domain-containing 3) gene has recently been identified as a causative gene of hypertrophic cardiomyopathy (HCM). However, the pathogenicity of FHOD3 variants remains to be evaluated. This study analyzed the spectrum of FHOD3 variants in a large HCM and control cohort, and explored its correlation with the disease. Methods and Results The genetic analysis of FHOD3 was performed using the whole exome sequencing data from 1000 patients with HCM and 761 controls without HCM. A total of 37 FHOD3 candidate variants were identified, including 25 missense variants and 2 truncating variants. In detail, there were 27 candidate variants detected in 33 (3.3%) patients with HCM, which was significantly higher than in the 12 controls (3.3% versus 1.6%; odds ratio, 2.13; P<0.05). On the basis of familial segregation, we identified one truncating variant (c.1286+2delT) as a causal variant in 4 patients. Furthermore, the FHOD3 candidate variant experienced significantly more risk of cardiovascular death and all-cause death (adjusted hazard ratio [HR], 3.71; 95%, 1.32-8.59; P=0.016; and adjusted HR, 3.02; 95% CI, 1.09-6.85; P=0.035, respectively). Conclusions Our study suggests that FHOD3 is a causal gene for HCM, and that the presence of FHOD3 candidate variants is an independent risk for cardiovascular death and all-cause death in HCM.
Keywords: cardiovascular events; formin homology 2 domain‐containing 3; genetic testing; hypertrophic cardiomyopathy.
Conflict of interest statement
None.
Figures


Similar articles
-
Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies.Nat Rev Cardiol. 2022 Mar;19(3):151-167. doi: 10.1038/s41569-021-00608-2. Epub 2021 Sep 15. Nat Rev Cardiol. 2022. PMID: 34526680 Review.
-
Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy.J Am Coll Cardiol. 2018 Nov 13;72(20):2457-2467. doi: 10.1016/j.jacc.2018.10.001. J Am Coll Cardiol. 2018. PMID: 30442288
-
Exome sequencing identifies a FHOD3 p.S527del mutation in a Chinese family with hypertrophic cardiomyopathy.J Gene Med. 2020 Mar;22(3):e3146. doi: 10.1002/jgm.3146. Epub 2020 Jan 14. J Gene Med. 2020. PMID: 31742804
-
Deletions of specific exons of FHOD3 detected by next-generation sequencing are associated with hypertrophic cardiomyopathy.Clin Genet. 2020 Jul;98(1):86-90. doi: 10.1111/cge.13759. Epub 2020 May 11. Clin Genet. 2020. PMID: 32335906
-
Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives.J Am Coll Cardiol. 2012 Aug 21;60(8):705-15. doi: 10.1016/j.jacc.2012.02.068. Epub 2012 Jul 11. J Am Coll Cardiol. 2012. PMID: 22796258 Review.
Cited by
-
A novel splice-site FHOD3 founder variant is a common cause of hypertrophic cardiomyopathy in the population of the Balkans-A cohort study.PLoS One. 2023 Dec 5;18(12):e0294969. doi: 10.1371/journal.pone.0294969. eCollection 2023. PLoS One. 2023. PMID: 38051749 Free PMC article.
-
Impact of Genetic Testing on the Diagnosis, Management, and Prognosis of Hypertrophic Cardiomyopathy: A Systematic Review.Cureus. 2024 Oct 7;16(10):e70993. doi: 10.7759/cureus.70993. eCollection 2024 Oct. Cureus. 2024. PMID: 39507141 Free PMC article. Review.
-
Human formin FHOD3-mediated actin elongation is required for sarcomere integrity in cardiomyocytes.bioRxiv [Preprint]. 2025 Apr 27:2024.10.13.618125. doi: 10.1101/2024.10.13.618125. bioRxiv. 2025. Update in: Elife. 2025 Jul 15;13:RP104048. doi: 10.7554/eLife.104048. PMID: 39464085 Free PMC article. Updated. Preprint.
-
Human formin FHOD3-mediated actin elongation is required for sarcomere integrity in cardiomyocytes.Elife. 2025 Jul 15;13:RP104048. doi: 10.7554/eLife.104048. Elife. 2025. PMID: 40663059 Free PMC article.
-
Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies.Nat Rev Cardiol. 2022 Mar;19(3):151-167. doi: 10.1038/s41569-021-00608-2. Epub 2021 Sep 15. Nat Rev Cardiol. 2022. PMID: 34526680 Review.
References
-
- Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study: coronary artery risk development in (young) adults. Circulation. 1995;92:785–789. DOI: 10.1161/01.CIR.92.4.785. - DOI - PubMed
-
- Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:2761–2796. DOI: 10.1161/CIR.0b013e318223e230. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases